Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus EMGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus EMGEL.
BACTROBAN vs EMGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 mL/min).
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Category C
Category C
Topical Antibiotic
Topical Antibiotic